Copy
Welcome!

Jump here directly to:



TOPIC  Cardiotoxicity of chemotherapeutic agents

NEWS   US User Meeting, Niels' Interview & Dynamic Clamp

 


  TOPIC   

Cardiotoxicity of chemotherapeutic agents

Cardio-oncology: An emerging subspeciality


New cancer therapeutics have led to longer life-expectancy for cancer patients. However, treatment-related co-morbidities such as cardiac toxicity have become an issue for cancer survivors. Cardiovascular complications of cancer therapeutic agents can have a dramatic effect on the quantity and quality of the life of cancer surviving patients. Many effective cancer treatments, including the anthracyclines such as doxorubicin, are associated with severe cardiotoxicity including  cardiomyopathy, thrombosis and hypertension. However, because these anti-cancer agents are so effective at prolonging life, the cardiotoxicity risks must be weighed up against the potential benefit of the treatment. This has led to the emergence of a new discipline, cardio-oncology, also known as oncocardiology, to facilitate effective cancer treatment whilst minimizing cardiovascular side effects.
Assessing cardiovascular risk of chemotherapeutic agents

It is important to be able to assess the cardiotoxic risk of new and existing cancer treatments in order to facilitate cardiovascular health during chemotherapy. Human induced pluripotent stem cell-derived cardiomoycytes (hiPSC-CMs) are an excellent tool for this purpose. Cancer drugs, e.g. paclitaxel, or Taxol as it is also known, shown here on the right causes a decrease in the base impedance, i.e. a change in morphology or cell contact indicative of toxicity, when measured with the CardioExcyte 96. Tween induces 100% cell death and is shown as a positive control. Paclitaxel shows a time- and concentration-dependent effect on base impedance indicating it's toxicity on human cardiomyocytes. With continuing advancements in hiPSC-CMs, it may soon be possible to test cardiotoxicity of cancer therapeutic regimes on patient-derived hiPSC-CMs in order to test personalized toxicity risk which takes into account factors such as genetic and sex variables.

Cardio-oncology: Recommended Assays, Cell Lines and Literature


Recommended assays:
  • CardioExcyte 96 (contractility, toxicity and extracellular field potentials)

Recommended Cardio-oncology Literature:
 
For more information read our Application Note
 
Cancer therapeutic agents paclitaxel and the combination therapy cyclophosphamide, doxorubicin and 5-Fluorouracil were tested for toxicity on human stem cell-derived cardiomyocytes using the CardioExcyte 96. Read our Application Note and poster from the SOT conference to find out more.

 

   NEWS   

US User Meeting, Niels' Interview & Dynamic Clamp

US User Meeting at the end of May

 
Mark your calendar for the upcoming US User Meeting, which will be held on the 28. - 29. May in Boston, USA.
If you are interested in presenting your work as an oral presentation or poster, please send an e-mail to Rodolfo Haedo.
More information is available soon here.

 
Register for the User Meeting

SURFE²R N1 - Win this platform for 6 Months!

 
Do not miss this opportunity to win a free SURFE²R N1 for a 6-month period!

All you need to do is send us your research proposal to take part in the competition.

Find out more about the SURFE²R N1 instrument here and about the grant application here.

Interview with Niels Fertig


February 2019: Niels was asked to give an interview to Gregory Qushair (Alésia Consulting) about the beginning, the present and the future of Nanion Technologies.
Read the full story here (on page 43 - 45).

Snapshot of the Month


A jovial Tim Strassmaier at the 63rd Annual Meeting of the 2019 Biophysical Society which took place on 02 - 06. March in Baltimore, USA.
As usual, Nanion was involved in many activities including Poster Presentations, providing instructions on how to participate in our latest PORT-A-PATCH MINI CONTEST, how to WIN A SURFE²R N1 and various Oral Presentations. Additionally, on the final day of the BPS Conference, Nanion organized a customer dinner at the Baltimore World Trade Center which was attended by our international teams and clients.

You can now keep up with our latest news on our corporate blog here.

Dynamic Patch Clamp in the Pipeline


We are pleased to announce that the fully automated dynamic clamp add-on for the Patchliner will be available soon!
Read more about our newest Patchliner Add-on here.

Latest Publications


Patchliner:
Avoiding hERG-liability in drug design via synergetic combinations of different (Q)SAR methodologies and data sources: a case study in an industrial setting.
Hanser T. et al., Journal of Cheminformatics (2019)
Download here.

Patchliner:
MAP4K4 Inhibition Promotes Survival of Human Stem Cell-Derived Cardiomyocytes and Reduces Infarct Size In Vivo.
Fiedler L.R. et al., Cell Stem Cell (2019)
Download here.

Port-a-Patch & Vesicle Prep Pro:
Minor sequence modifications in temporin B cause drastic changes in antibacterial potency and selectivity by fundamentally altering membrane activity.
Manzo G. et al., Nature Scientific Reports (2019)
Download here.

Port-a-Patch:
High-resolution experimental and computational electrophysiology reveals weak β-lactam binding events in the porin PorB.
Bartsch A. et al., Nature Scientific Reports (2019)
Download here.

CardioExcyte 96:
Particulate matter 2.5 induced arrhythmogenesis mediated by TRPC3 in human induced pluripotent stem cell-derived cardiomyocytes.
Cai C. et al. Archives of Toxicology (2019)
Download here.

Orbit 16:
Real-time monitoring β-lactam/β-lactamase inhibitor (BL/BLI) mixture towards the bacteria porin pathway at single molecule level.
Wang J. et al. Analytical and Bioanalytical Chemistry (2019)
Download here.

Mark Your Calendar


31. March - 05. April 2019:
Gordon Research Conference -  Cardiac Arrhythmia Mechanisms (Lucca, Italy).
Meet Krisztina Juhasz.

15. - 17. May 2019:
The Reci VII. 2019 Conference (Cáceres, Spain). Meet Conrad Weichbrodt and Maria Giustina Rotordam.
Share
Share
Tweet
Forward
Copyright © 2019 Nanion Technologies GmbH, All rights reserved.


Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list